422560-40-5

Basic information

• Product Name: 2-(4-BROMO-PHENYL)-N-HYDROXY-ACETAMIDINE
• Synonyms: 2-(4-bromophenyl)-N'-hydroxyacetimidamide;BENZENEETHANIMIDAMIDE,4-BROMO-N-HYDROXY-;2-(4-BROMO-PHENYL)-N-HYDROXY-ACETAMIDINE;B64074
• CAS NO: 422560-40-5
• Molecular Formula: C₈H₉BrN₂O
• Molecular Weight: 229.07
• Product Categories: pharmacetical
• Mol File: 422560-40-5.mol
• Article Data: 10

Chemical Properties

• Melting Point: 132-134℃
• Boiling Point: 397.6°Cat760mmHg
• Flash Point: 194.3°C
• Appearance: White/Crystalline Solid
• Density: 1.58g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 14.63±0.50(Predicted)
• CAS DataBase Reference: 2-(4-BROMO-PHENYL)-N-HYDROXY-ACETAMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-BROMO-PHENYL)-N-HYDROXY-ACETAMIDINE(422560-40-5)
• EPA Substance Registry System: 2-(4-BROMO-PHENYL)-N-HYDROXY-ACETAMIDINE(422560-40-5)

Safety Data

• Hazardous Substances Data: 422560-40-5(Hazardous Substances Data)

Usage

General Description

The chemical compound 2-(4-BROMO-PHENYL)-N-HYDROXY-ACETAMIDINE, also known as bromhexine hydrochloride, is a medication that is used as a mucolytic agent to help break up and expel mucus in the airways. It works by increasing the production of respiratory tract fluid, which helps make the mucus less sticky and easier to cough up. Bromhexine hydrochloride is commonly used to treat conditions such as chronic bronchitis, asthma, and other respiratory tract infections. It is available in various forms such as tablets, syrup, and solution for inhalation. However, as with any medication, it is important to use it only as directed by a healthcare professional.

Upstream product

• 16532-79-9 4-Bromophenylacetonitrile 
• 5470-11-1 hydroxylamine hydrochloride 

Downstream Products

• 1345020-62-3 (S)-benzyl-1 (3-(4-bromobenzyl)-1,2,4-oxadiazol-5-yl)benzylcarbamate 
• 1345020-61-2 (S)-benzyl 1-(3-(4-bromobenzyl)-1,2,4-oxadiazol-5-yl)-2-methylpropylcarbamate 
• 1345020-59-8 3-(4-bromobenzyl)-5-(3-phenylpropyl)-1,2,4-oxadiazole 
• 1345020-58-7 3-(4-bromobenzyl)-5-(4-methylbenzyl)-1,2,4-oxadiazole 
• 1345020-57-6 3-(4-bromobenzyl)-5-(3-methylbenzyl)-1,2,4-oxadiazole 
• 1028344-70-8 C₁₃H₁₃BrN₂O₃ 
• 1208553-26-7 C₁₃H₁₁BrN₂O₄ 
• 1027969-07-8 (S)-2-Amino-2-[3-(4-bromo-benzyl)-[1,2,4]oxadiazol-5-yl]-ethanol 
• 1025987-77-2 (S)-1-[3-(4-Bromo-benzyl)-[1,2,4]oxadiazol-5-yl]-ethylamine 

Relevant articles and documents

Novel O-acylated amidoximes and substituted 1,2,4-oxadiazoles synthesised from (+)-ketopinic acid possessing potent virus-inhibiting activity against phylogenetically distinct influenza A viruses

This article describes the synthesis and antiviral activity evaluation of new substituted 1,2,4-oxadiazoles containing a bicyclic substituent at position 5 of the heterocycle and O-acylated amidoximes as precursors for their synthesis. New compounds were

Nitrobenzofurazan derivatives of N′-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1

Tryptophan metabolism through the kynurenine pathway is considered as a crucial mechanism in immune tolerance. Indoleamine 2,3-dioxygenase 1 (IDO1) plays a key role in tryptophan catabolism in the immune system and it is also considered as an important therapeutic target for the treatment of cancer and other diseases that are linked with kynurenine pathway. In this study, a series of nitrobenzofurazan derivatives of N′-hydroxybenzimidamides (1) and N′-hydroxy-2-phenylacetimidamides (2) were synthesized and their inhibitory activities against human IDO1 enzyme were tested using in-vitro and cellular enzyme activity assay. The optimization leads to the identification of potent compounds, 1d, 2i and 2k (IC50 = 39-80 nM), which are either competitive or uncompetitive inhibitors of IDO1 enzyme. These compounds also showed IDO1 inhibition potencies in the nanomolar range (IC50 = 50-71 nM) in MDA-MB-231 cells with no/negligible amount of cytotoxicity. The stronger selectivity of the potent compounds for IDO1 enzyme over tryptophan 2,3-dioxygenase (TDO) enzyme (312-1593-fold) also makes them very attractive for further immunotherapeutic applications.

DUAL-ACTING ANTIHYPERTENSIVE AGENTS

In one aspect, the invention relates to compounds having the formula: wherein: Ar, r, Z, X, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.